Mellozzan[® ](melatonin) have gained marketing approval in Germany and Austria
As the first countries outside of Scandinavia, EQL's key product Mellozzan[®] has now gained marketing approval by the Health Authorities in Germany and Austria, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH & Co. KG. Launch of Mellozzan in Germany and Austria are planned for 2024, subject to reimbursement approvals and manufacturing capabilities. In addition to Germany and Austria the licensee also has ongoing work for registrations and subsequent launches in the UK, Finland and Switzerland. Earlier this year Medice launched Mellozzan in
On 6 October, the Norwegian government presented its state budget proposal for 2024. The proposal contains elements potentially affecting Elkem's activities in Norway.CO2 compensation is a government scheme provided to avoid carbon leakage, i.e. where European industry is shut down and moved to countries without CO2 emissions tariffs, causing increased global emissions as well as the loss of green industrial jobs.
This applies to Elkem in Norway as compensation for CO2 costs included in the pricing of the CO2-free renewable power used in Elkem’s Norwegian production of silicon and
